These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3677073)

  • 1. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129.
    Meador J; Sweet P; Stupecky M; Wetzel M; Murray S; Gupta S; Slater L
    Cancer Res; 1987 Dec; 47(23):6216-9. PubMed ID: 3677073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells.
    Sweet P; Chan PK; Slater LM
    Cancer Res; 1989 Feb; 49(3):677-80. PubMed ID: 2910487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
    Slater LM; Sweet P; Stupecky M; Wetzel MW; Gupta S
    Br J Cancer; 1986 Aug; 54(2):235-8. PubMed ID: 3741759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Res; 1980 Apr; 40(4):1077-83. PubMed ID: 7357538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.
    Slater LM; Murray SL; Wetzel MW; Wisdom RM; DuVall EM
    J Clin Invest; 1982 Nov; 70(5):1131-4. PubMed ID: 6182160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Nissen NI
    Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.
    Slater LM; Sweet P; Stupecky M; Gupta S
    J Clin Invest; 1986 Apr; 77(4):1405-8. PubMed ID: 3457021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
    Seeber S; Osieka R; Schmidt CG; Achterrath W; Crooke ST
    Cancer Res; 1982 Nov; 42(11):4719-25. PubMed ID: 6889912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
    Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma.
    Murray SL; Du Vall EM; Slater LM
    Cancer Chemother Pharmacol; 1984; 13(1):69-70. PubMed ID: 6733845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Perez LM; Greer S
    Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of transplantable tumors in mice by monomethylformamide].
    Smoryzanova OA; Proskuriakov SIa; Dedenkov AN; Riabchenko NI
    Vopr Onkol; 1989; 35(8):967-70. PubMed ID: 2800445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Dec; 38(12):4722-7. PubMed ID: 719649
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of 5-fluorouracil in combination with methoxyphenyl maleamic acid in murine tumors.
    Indap MA; Ambaye RY
    J Postgrad Med; 1991 Oct; 37(4):211-5. PubMed ID: 1841970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of exogenous DNA on the growth of transplantable tumors].
    Nikolin VP; Popova NA; Sebeleva TE; Strunkin DN; Rogachev VA; Semënov DV; Bogachev SS; Iakubov LA; Shurdov MA
    Vopr Onkol; 2006; 52(1):66-9. PubMed ID: 16715707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of various degrees of tumor sensitivity to olivomycin].
    Reztsova VV
    Antibiotiki; 1981 May; 26(5):391-3. PubMed ID: 7259149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Jun; 38(6):1785-91. PubMed ID: 647687
    [No Abstract]   [Full Text] [Related]  

  • 19. Downregulation of taurine uptake in multidrug resistant Ehrlich ascites tumor cells.
    Poulsen KA; Litman T; Eriksen J; Mollerup J; Lambert IH
    Amino Acids; 2002 Jun; 22(4):333-50. PubMed ID: 12107761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
    Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
    Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.